Navigation Links
Orexigen(R) Therapeutics Schedules September 30, 2009 Teleconference and Webcast to Discuss Phase 2b Trial Results From Second Obesity Drug Candidate, Empatic(TM)
Date:9/29/2009

SAN DIEGO, Sept. 29 /PRNewswire-FirstCall/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, plans to announce the results of a Phase 2b trial for Empatic(TM) on Wednesday, September 30, 2009 before the markets open. The announcement will be followed by a live webcast and conference call at 8:30 a.m. Eastern time.

Orexigen management will host the call and webcast to discuss the results of this clinical trial and answer questions. The live call may be accessed by phone by calling (800).884.5695 (domestic) or (617).786.2960 (international), participant code 64389662. The webcast can be accessed live on the investor relations section of the Orexigen web site at www.orexigen.com, and will be archived for 14 days following the call.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead investigational product, Contrave, has completed Phase 3 clinical trials and is on track for a regulatory submission with the FDA in the first half of 2010. The Company's second product candidate, Empatic, has completed Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches. Further information about the Company can be found at http://www.orexigen.com.

SOURCE Orexigen Therapeutics, Inc.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results
2. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
3. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
4. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
5. Oxygen Biotherapeutics, Inc. Receives Phase II Trial Approval in Israel
6. Pivotal Registration Trial of OPAXIO Maintenance Therapy in First-Line Ovarian Cancer Reaches Enrollment Milestone of 600 patients, Cell Therapeutics and the Gynecologic Oncology Group Discuss Potential for Early Interim Analysis
7. Artielle ImmunoTherapeutics Announces Positive Results of Phase 1 Multiple Sclerosis Trial
8. Tobira Therapeutics Inc. Announces In Vitro Data of TBR-652 for the Treatment of HIV
9. Calixa Therapeutics to Make Multiple Presentations on CXA-101 and CXA-101/tazobactam at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
10. InfraReDx to Showcase the LipiScan(TM) Coronary Imaging System at the Cardiovascular Research Foundations (CRF) Annual Transcatheter Cardiovascular Therapeutics (TCT) Scientific Meeting
11. Oxygen Biotherapeutics, Inc. Submits Milestone Achievement Notice to Vatea Fund
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 8, 2016 KEY FINDINGS ... of the market in 2016 and is expected to ... attributed to a large number of surgical procedures that ... largest share in the patient temperature management market.) Patient ... reducing loss of blood during surgeries, lowering the risks ...
(Date:12/8/2016)... Research and Markets has announced the addition of the ... Application, Usability - Forecast to 2025" report to their offering. ... , , ... grow at a CAGR of around 3.2% from 2015 to 2025. ... advancements in extracellular microelectrode arrays and intracellular microelectrodes, research in left-to-right ...
(Date:12/8/2016)... , Dec. 8, 2016  Valeant Pharmaceuticals ... TSX: VRX) ("Valeant") today announced positive results from ... study to assess the safety and efficacy of ... treatment of plaque psoriasis. Within ... with moderate to severe psoriasis, IDP-118 showed statistical ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... ... announce that “Natural Language Processing–Enabled and Conventional Data Capture Methods for Input to ... Medical Informatics . , Results of the comparative usability study demonstrate that a ...
(Date:12/8/2016)... ... 2016 , ... With the increasing demand for dental implants, the National Association ... to inform dentists and patients about the safety issues related to dental restorations. According ... the U.S. is projected to reach $6.4 billion in 2018 with more than 30 ...
(Date:12/8/2016)... ... 08, 2016 , ... Launching of the ... Instance Manager architecture, meeting the needs of multichannel growth and doubling the ... auto-dialing system without agents, Presence Robodialer, provides greater operational capacity, administrative flexibility ...
(Date:12/8/2016)... ... December 08, 2016 , ... California Senate Bill (SB) 863, signed into ... claim in 2013 and 2014, according to CompScope™ Medical Benchmarks for California, 17th ... According to the study, medical payments per claim in California decreased 4 percent in ...
(Date:12/8/2016)... Rock, AR (PRWEB) , ... December 08, 2016 ... ... providing insurance and financial planning services from offices headquartered in Little Rock, has ... Food Pantry. , According to the National Foundation to End Senior Hunger, Arkansas ...
Breaking Medicine News(10 mins):